aad 2026 - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,842 +0.87%

DJIA 48,355 +0.93%

Nasdaq 25,100 +0.83%

DAX 23,938 -0.11%

Gold $4,196 +0.16%

Oil $95.65 -1.08%

BTC $72,423 +1.48%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,220 +0.50%

S&P 500 6,842 +0.87%

DJIA 48,355 +0.93%

Nasdaq 25,100 +0.83%

DAX 23,938 -0.11%

Gold $4,196 +0.16%

Oil $95.65 -1.08%

BTC $72,423 +1.48%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,220 +0.50%

aad 2026

AbbVie Dermatology Data spotlight Skyrizi and Rinvoq dermatology treatments in premium product focus

Pharma & Healthcare·Stocks·USA

AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors

By Maik Kemper • Mar 27, 2026

AbbVie Dermatology Data spotlight Skyrizi and Rinvoq dermatology treatments in premium product focus

Pharma & Healthcare·Stocks·USA

AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors

By Maik Kemper • Mar 27, 2026

Can AbbVie’s latest dermatology data at AAD 2026 really secure its post-Humira growth story in immunology? Maik Kemper Editor in Chief Our robust evidence across…